Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on June 16, 2021. The filing discloses positive interim data from a Phase 1 clinical trial of the company's investigational GLP-1/glucagon dual receptor agonist, ALT-801, in healthy overweight and obese volunteers.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and future operational plans.
Material Changes and Clinical Results
The primary material event is the announcement of interim results from a 12-week, Phase 1, placebo-controlled trial of ALT-801:
- Weight Loss Efficacy: At Week 6, the 1.8 mg once-weekly subcutaneous dose achieved a mean weight loss of 5.4% compared to a 0.9% weight gain in the placebo group (net change of 6.3%, p < .0001). This surpassed the pre-established target of 2% weight loss.
- Dose Response: A lower 1.2 mg dose cohort achieved a mean weight loss of 1.8% (net change from placebo of 2.7%, p < .05).
- Tolerability: ALT-801 was well-tolerated without dose titration. Transient nausea rates were 14.3% at 1.2 mg and 22.2% at 1.8 mg. All nausea events at the 1.8 mg dose were mild. There were no reports of vomiting, diarrhea, or constipation.
- Study Limitations: The study population was young (mean age 29.8) and non-diabetic, resulting in insufficient subjects with liver fat levels suitable for MRI-PDFF analysis.
Guidance, Outlook, and Risks
Future Plans:
- The company plans to expand enrollment criteria to include diabetic and older subjects.
- A separate 12-week Phase 1b study for subjects with non-alcoholic fatty liver disease (NAFLD) is anticipated to commence in Q3 2021 in the United States.
- A 52-week biopsy-driven NASH trial is planned to initiate in Q1 2022.
Risks and Contingencies:
- Forward-looking statements are subject to risks including the impact of the COVID-19 pandemic on regulatory reviews, manufacturing, and clinical site access.
- Uncertainties regarding the reliability of study results, potential adverse effects, and the ability to manufacture clinical trial materials on anticipated timelines.
- Success of future product advancements and regulatory approval prospects are not guaranteed.
Investor Verification Checklist
- Verify the full 12-week data readout for the ALT-801 Phase 1 trial expected in Q3 2021.
- Confirm the commencement date and enrollment progress of the Phase 1b NAFLD study in the United States.
- Monitor the timeline for the initiation of the 52-week biopsy-driven NASH trial scheduled for Q1 2022.
- Review the company's cash position and burn rate in recent 10-Q or 10-K filings, as this 8-K does not contain financial data.